Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.[ ] It is a retinoid;
Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Medical uses
In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.
In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.
Side effects
Most
Adverse effect of topical trifarotene for the treatment of acne are at the location side and transient, such as application site irritation, allergic dermatitis, skin irritation and sunburn.
Even though systemic absorption is very low,
use of trifarotene is still
contraindicated during pregnancy
because of the known risk of
teratogenicity of the overall class of drugs trifarotene belongs to, retinoids.
Society and culture
Legal status
Trifarotene was approved for medical use in the United States in October 2019,
in Canada in November 2019,
and in Australia in January 2021.
